Drug Profile
Research programme: 1 phosphatidylinositol 3-kinase inhibitors - Oncothyreon
Alternative Names: PX-867Latest Information Update: 04 Feb 2011
Price :
$50
*
At a glance
- Originator Oncothyreon
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Feb 2011 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)